BIVI
name pending profile ingest
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 17 | -1 | 1.03M | $2.00M | +1 | −2 |
| Q1 2026 | 18 | -3 | 421.63K | $589,117 | +2 | −5 |
| Q4 2025 | 21 | +1 | 489.01K | $548,442 | +1 | n/a |
| Q3 2025 | 7 | +1 | 421.57K | $800,977 | +3 | −2 |
| Q2 2025 | 4 | -1 | 707.89K | $654,800 | n/a | −1 |
| Q1 2025 | 3 | -1 | 175.66K | $172,147 | n/a | −1 |
| Q4 2024 | 4 | +2 | 290.76K | $581,530 | +2 | n/a |
| Q3 2024 | 1 | -2 | 38.17K | $45,811 | n/a | −2 |
| Q2 2024 | 3 | n/a | 265.86K | $106,482 | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 231.66K | n/a | $92,786 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | AQR Capital Management ✦ | 20.15K | n/a | $8,071 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Two Sigma Investments ✦ | 14.05K | n/a | $5,625 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 8 holders, 2.23M shares, $691,052 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer · Chief Financial… · 2.50K sh @ 2.18 · $5,450
Director · 727 sh @ 2.16 · $1,570
Officer · Chief Medical Officer · 4.84K sh @ 2.16 · $10,461
Officer, Director · President & CEO · 15.21K sh @ 2.08 · $31,637
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology